Ключевые слова
Как цитировать
Аннотация
В статье представлены результаты голосования I Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2024», посвященного наиболее актуальным и спорным вопросам диагностики, хирургической тактики, лучевой терапии и системного лечения данной категории пациентов. Под председательством член-корреспондента РАН, профессора Владимира Федоровича Семиглазова в международном консенсусе приняли участие 38 экспертов в области диагностики и лечения рака молочной железы (РМЖ), проголосовавших в ходе прямого эфира по 32 вопросам, разделенным на блоки раннего и метастатического РМЖ. Проведение II Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2025» запланировано со 2 по 5 июля 2025 года.
Библиографические ссылки
Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18(7): 1133-1144.-DOI: https://doi.org/10.1093/annonc/mdm271.-URL: https://www.sciencedirect.com/science/article/pii/S0923753419412209?via%3Dihub.
Balic M., Thomssen C., Würstlein R., et al. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care. 2019; 14 (2): 103-110.-DOI: https://doi.org/10.1159/000499931.-URL: https://karger.com/brc/article/14/2/103/53480/St-Gallen-Vienna-2019-A-Brief-Summary-of-the.
Burstein H.J., Curigliano G., Thürlimann B., et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. 2021; 32(10): 1216-35.-DOI: https://doi.org/10.1016/j.annonc.2021.06.023.-URL: https://www.sciencedirect.com/science/article/pii/S0923753421021049?via%3Dihub.
июля - 7 июля 2024 года X Петербургский международный Онкологический форум «Белые ночи 2024». Белые ночи. Автономная некоммерческая научномедицинская организация «Вопросы онкологии».-URL: https://forum-onco.ru/. [July 3 - July 7, 2024 10th St. Petersburg International Oncological Forum «White Nights 2024». White Nights. Autonomous non-commercial scientific and medical organization «Voprosy Onkologii».-URL: https://forum-onco.ru/ (In Rus)].
Wolff A.C., Hammond M.E.H., Allison K.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline focused update. Arch Pathol Lab Med. 2018; 142(11): 1364-82.-DOI: https://doi.org/10.1200/JCO.2018.77.8738.-URL: https://ascopubs.org/doi/10.1200/JCO.2018.77.8738.
Tarantino P., Viale G., Press M.F., et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2023; 34(8): 645-59.-DOI: https://doi.org/10.1016/j.annonc.2023.05.008.-URL: https://www.sciencedirect.com/science/article/pii/S0923753423006932?via%3Dihub.
Boughey J.C., Rosenkranz K.M., Ballman K.V., et al. Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance). J Clin Oncol Off J Am Soc Clin Oncol. 2023; 41(17): 3184-93.-DOI: https://doi.org/10.1200/JCO.22.02553.-URL: https://ascopubs.org/doi/10.1200/JCO.22.02553.
Smith I., Robertson J., Kilburn L., et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020; 21(11): 1443-54.-DOI: https://doi.org/10.1016/S1470-2045(20)30458-7.-URL: https://www.sciencedirect.com/science/article/pii/S1470204520304587?via%3Dihub.
Balic M., Thomssen C., Gnant M., et al. St. Gallen/Vienna 2023: optimization of treatment for patients with primary breast cancer - a brief summary of the consensus discussion. Breast Care Basel Switz. 2023; 18(3): 213-22.-DOI: https://doi.org/10.1159/000530584.-URL: https://karger.com/brc/article/18/3/213/836657/St-Gallen-Vienna-2023-Optimization-of-Treatment.
Клинические рекомендации. Рак молочной железы. Рубрикатор клинических рекомендаций. Министерство здравоохранения Российской Федерации.-URL: https://cr.minzdrav.gov.ru/schema/379_4. [Clinical guidelines. Breast cancer. Rubricator of clinical recommendations. Ministry of Health of the Russian Federation.-URL: https://cr.minzdrav.gov.ru/schema/379_4.]
Metcalfe K., Gershman S., Ghadirian P., et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014; 348: g226.-DOI: https://doi.org/10.1136/bmj.g226.-URL: https://www.bmj.com/content/348/bmj.g226.
Имянитов Е.Н., Соколенко А.П., Берлев И.В., et al. Носительство мутаций в генах BRCA1 и BRCA2 у здоровых женщин и мужчин: ДНК-тестирование, диагностические мероприятия и профилактика рака. Вопросы онкологии. 2017; 63(2): 190-198.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/692/503. [Imyanitov E.N., Sokolenko A.P., Berlev I.V., et al. Presence of BRCA1 and BRCA2 in healthy women and men: DNA testing, diagnostic activities and cancer prevention. Voprosy Onkologii = Problems in Oncology. 2017; 63(2): 190-198.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/692/503. (In Rus)].
Gennari A., André F., Barrios C.H., et al. Breast Cancer Pocket Guideline 2024. ESMO.-URL: https://interactiveguidelines.esmo.org/esmo-web-app/toc/index.php?subjectAreaID=8&loadPdf=1.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. Version 5. 2024.-URL: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
Morrow M., Van Zee K.J., Solin L.J., et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol. 2016; 6(5): 287-95.-DOI: https://doi.org/10.1016/j.prro.2016.06.011.-URL: https://www.sciencedirect.com/science/article/abs/pii/S1879850016301096?via%3Dihub.
Namdar Z.M., Omidifar N., Arasteh P., et al. How accurate is frozen section pathology compared to permanent pathology in detecting involved margins and lymph nodes in breast cancer? World J Surg Oncol. 2021; 19(1): 261.-DOI: https://doi.org/10.1186/s12957-021-02365-5.-URL: https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02365-5.
Kolben T., Schwarz T.M., Goess C., et al. Surgical management of ipsilateral breast tumor recurrence. Int J Surg Lond Engl. 2015; 23(Pt A): 141-6.-DOI: https://doi.org/10.1016/j.ijsu.2015.08.084.-URL: https://www.sciencedirect.com/science/article/pii/S1743919115012649?via%3Dihub.
Smanykó V., Mészáros N., Újhelyi M., et al. Second breast-conserving surgery and interstitial brachytherapy vs. salvage mastectomy for the treatment of local recurrences: 5-year results. Brachytherapy. 2019; 18(3): 411-9.-DOI: https://doi.org/10.1016/j.brachy.2019.02.004.-URL: https://www.sciencedirect.com/science/article/abs/pii/S1538472118307529?via%3Dihub.
Liu J., Mao K., Jiang S., et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget. 2016; 7(17): 24848-59.-DOI: https://doi.org/10.18632/oncotarget.6664.-URL: https://www.oncotarget.com/article/6664/text/.
Mamounas E., Bandos H., White J., et al. Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304. 2023.-URL: https://scholarlyworks.beaumont.org/radiation_oncology_confabstract/174/.
de Boniface J., Filtenborg Tvedskov T., Rydén L., et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024; 390(13): 1163-75.-DOI: https://doi.org/10.1056/NEJMoa2313487.-URL: https://www.nejm.org/doi/10.1056/NEJMoa2313487.
Vaidya J.S., Bulsara M., Saunders C., et al. Effect of delayed targeted intraoperative radiotherapy vs whole-breast radiotherapy on local recurrence and survival. JAMA Oncol. 2020; 6(7): e200249.-DOI: https://doi.org/10.1001/jamaoncol.2020.0249.-URL: https://jamanetwork.com/journals/jamaoncology/fullarticle/2763397.
Orecchia R., Veronesi U., Maisonneuve P., et al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021; 22(5): 597-608.-DOI: https://doi.org/10.1016/S1470-2045(21)00080-2.-URL: https://www.sciencedirect.com/science/article/pii/S1470204521000802?via%3Dihub.
Loibl S., Mano M., Untch M., et al. Abstract GS03-12: Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. Cancer Res. 2024; 84(9_Supplement): GS03-12-GS03-12.-DOI: https://doi.org/10.1158/1538-7445.SABCS23-GS03-12.-URL: https://aacrjournals.org/cancerres/article/84/9_Supplement/GS03-12/743582/Abstract-GS03-12-Phase-III-study-of-adjuvant-ado.
Doucet L., Moreau-Bachelard C., Gourmelon C., et al. Long-term outcomes of patients with HER2+ breast cancer with small-size residual disease (≤ypT1) in the absence of pathological response after trastuzumab-based neoadjuvant chemotherapy and without adjuvant T-DM1: A mo-nocentric retrospective study. J Clin Oncol. 2020; 38(15_suppl): 589-589.-DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.589.-URL: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.589.
Goss P.E., Ingle J.N., Pritchard K.I., et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016; 375(3): 209-19.-DOI: https://doi.org/10.1056/NEJMoa1604700.-URL: https://www.nejm.org/doi/10.1056/NEJMoa1604700.
Gnant M., Fitzal F., Rinnerthaler G., et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 2021; 385(5): 395-405.-DOI: https://doi.org/10.1056/NEJMoa2104162.-URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2104162.
Rastogi P., O'Shaughnessy J., Martin M., et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024; 42(9): 987-993.-DOI: 10.1200/JCO.23.01994.-URL: https://ascopubs.org/doi/10.1200/JCO.23.01994.
Yilmaz C., Cavdar D.K. Biomarker discordances and alterations observed in breast cancer treated with neoadjuvant chemotherapy: causes, frequencies, and clinical significances. Curr Oncol. 2022; 29(12): 9695-710.-DOI: https://doi.org/10.3390/curroncol29120761.-URL: https://www.mdpi.com/1718-7729/29/12/761.
Geyer C.E., Garber J.E., Gelber R.D., et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2022; 33(12): 1250-68.-DOI: https://doi.org/10.1016/j.annonc.2022.09.159.-URL: https://www.sciencedirect.com/science/article/pii/S0923753422041655?via%3Dihub.
Moore H.C.F., Unger J.M., Phillips K.A., et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015; 372(10): 923-32.-DOI: https://doi.org/10.1056/NEJMoa1413204.
Partridge A.H., Niman S.M., Ruggeri M., et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023; 388(18): 1645-56.-DOI: https://doi.org/10.1056/NEJMoa1413204.-URL: https://www.nejm.org/doi/10.1056/NEJMoa1413204.
Evans D.G., Woodward E.R., Bajalica-Lagercrantz S., et al. Germline TP53 testing in breast cancers: why, when and how? Cancers. 2020; 12(12): 3762.-DOI: https://doi.org/10.3390/cancers12123762.-URL: https://www.mdpi.com/2072-6694/12/12/3762.
Lambertini M., Arecco L., Woodard T.L., et al. Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2023; 43: e390442.-DOI: https://doi.org/10.1200/EDBK_390442.-URL: https://ascopubs.org/doi/10.1200/EDBK_390442.
Sonke G., van Ommen A., Wortelboer N., et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol. 2023; 41(17_suppl): LBA1000–LBA1000. DOI: https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA1000.-URL: https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA1000.
Lu Y.S., Mahidin E.I.B.M., Azim H., et al. Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2024; 42(23): 2812-21.-DOI: https://doi.org/10.1200/JCO.24.00144.-URL: https://ascopubs.org/doi/10.1200/JCO.24.00144.
Valenza C., Trapani D., Gandini S., et al. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. Eur J Cancer Oxf Engl. 1990. 2023; 190: 112944.-DOI: https://doi.org/10.1016/j.ejca.2023.112944.-URL: https://www.sciencedirect.com/science/article/abs/pii/S0959804923002964?via%3Dihub.
Cardoso F., Paluch-Shimon S., Schumacher-Wulf E., et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024; 76: 103756.-DOI: https://doi.org/10.1016/j.breast.2024.103756.-URL: https://www.sciencedirect.com/science/article/pii/S0960977624000870?via%3Dihub.
Modi S., Jacot W., Yamashita T., et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine. 2022; 387(1): 9-20.-DOI: https://doi.org/10.1056/nejmoa2203690.
Coleman R., Hadji P., Body J.J., et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncol. 2020; 31(12): 1650-63.-DOI: https://doi.org/10.1016/j.annonc.2020.07.019.-URL: https://www.sciencedirect.com/science/article/pii/S0923753420399956?via%3Dihub.
Багрова С.Г., Басин Е.М., Борзов К.А., et al. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023 (13); #3s2: 45-58.-DOI: https://doi.org/10.18027/2224-5057-2023-13-3s2-2-45-58.-URL: https://rosoncoweb.ru/standarts/RUSSCO/2023/2023-39.pdf. [Bagrova S.G., Basin E.M., Borzov К.A., et al. Prevention and treatment of bone tissue in malignant neoplasms. Practical recommendations RUSSCO, part 2. Malignant Tumours. 2023 (13); #3s2: 45-58.-DOI: https://doi.org/10.18027/2224-5057-2023-13-3s2-2-45-58.-URL: https://rosoncoweb.ru/standarts/RUSSCO/2023/2023-39.pdf. (In Rus)].
Fehm T., Beck V., Banys M., et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol. 2009; 112(3): 605-9.-DOI: https://doi.org/10.1016/j.ygyno.2008.11.029.-URL: https://www.sciencedirect.com/science/article/abs/pii/S0090825808009761?via%3Dihub.
Yarom N., Shapiro C.L., Peterson D.E., et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2019; 37(25): 2270-90.-DOI: https://doi.org/10.1200/JCO.19.01186.-URL: https://ascopubs.org/doi/10.1200/JCO.19.01186.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2024